Join The Community

Summary

The product HGH Fragment 176-191, manufactured by Biogenix Pharma, was independently analyzed to verify its authenticity and potency. The sample was submitted by the manufacturer and tested by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control.

The analysis did not detect the labeled ingredient HGH Fragment 176-191 but instead found AOD-9604, a different but structurally similar peptide. The measured concentration of AOD-9604 was 4.16 mg, which is 16.8% below the labeled claim of 5 mg. Despite this misidentification, the product’s purity was 99.814%, indicating a high level of cleanliness in the manufacturing process.

The testing process began on 11 August 2024, with the sample received on 22 August 2024, and the analysis completed on 23 August 2024. This finding raises concerns about mislabeling or potential formulation errors. Given that HGH Fragment 176-191 and AOD-9604 are related peptides with overlapping functions—both being synthetic fragments of human growth hormone (HGH)—this substitution may have been a manufacturing oversight, a supply chain issue, or a labeling error.

Because the sample was submitted and paid for by the manufacturer, additional scrutiny is necessary to ensure consistency across different batches. Independent third-party testing is crucial for validating these findings and determining whether this misidentification is a widespread issue or an isolated case.

This report is provided as an educational resource to promote harm reduction and support informed decision-making for consumers.

Detailed Report

Product Overview

Sample Acquisition and Testing

Testing Results

SpecificationLabel ClaimMeasured ResultAccuracy (%)Purity (%)
HGH Fragment 176-1915 mg0 mg0%—
AOD-9604Not Listed4.16 mg83.2%99.814%

Key Findings

Verification Details

Evaluation of Manufacturer-Submitted Testing

This report raises concerns regarding the misidentification of the active ingredient. While the sample maintains high purity, the fact that HGH Fragment 176-191 was not detected and AOD-9604 was found instead presents several possible explanations:

  1. Manufacturing Error:
    • The facility may have accidentally substituted AOD-9604 for HGH Fragment 176-191 during formulation.
  2. Labeling or Supply Chain Issue:
    • HGH Fragment 176-191 and AOD-9604 share functional similarities, leading to possible mix-ups in bulk ingredient sourcing.
  3. Intentional Substitution:
    • If AOD-9604 was knowingly used as a substitute, this would indicate mislabeling rather than an accidental formulation error.

Key Similarities Between HGH Fragment 176-191 and AOD-9604

Both peptides are derived from human growth hormone (HGH) and are often marketed for fat loss and metabolic benefits. While they have distinct sequences and mechanisms, they serve similar purposes, which could explain the substitution.

However, consumers should be aware of exactly what they are purchasing, as these compounds have different regulatory statuses and potential effects. Accurate labeling is critical for informed use.

Since this sample was submitted and paid for by the manufacturer, additional independent third-party testing is necessary to determine whether this was an isolated case or a broader issue affecting multiple batches.

Conclusion

The analysis of Biogenix Pharma HGH Fragment 176-191 revealed that the expected ingredient was absent, and instead, AOD-9604 was detected at 4.16 mg (83.2% of the labeled claim).

While the product’s purity remains high (99.814%), the discrepancy raises serious concerns about labeling accuracy and ingredient sourcing. Whether this was a manufacturing mistake, labeling error, or intentional substitution, users must be cautious when evaluating peptide products.

This report highlights the importance of third-party validation and transparent supply chains to ensure product integrity. Consumers seeking HGH Fragment 176-191 should verify independent testing or seek alternative sources until this discrepancy is further investigated.

This report is published to support harm reduction efforts and help consumers make informed choices regarding peptide products.

Disclaimer

This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, these results highlight a significant discrepancy in the product’s composition. Readers are encouraged to interpret this information critically and compare findings with third-party independent lab testing.

Biogenix Pharma HGH Fragment 176-191